N-Deshydroxyethyl Dasatinib,
910297-51-7,
UNII-38T0L9673E,
PROTAC Bcr-Abl-binding moiety 1,
38T0L9673E,
N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-(1-piperazinyl)-4-pyrimidinyl]amino]-5-thiazolecarboxamide,
N-(2-Chloro-6-methyl-phenyl)-2-((2-methyl-6-piperazin-1-yl-pyrimidin-4-yl)amino)thiazole-5-carboxamide,
N-(2-Chloro-6-methyl-phenyl)-2-[(2-methyl-6-piperazin-1-yl-pyrimidin-4-yl)amino]thiazole-5-carboxamide,
N-(2-CHLORO-6-METHYLPHENYL)-2-[[2-METHYL-6-(PIPERAZIN-1-YL)-PYRIMIDIN-4-YL]AMINO]-5-THIAZOLECARBOXAMIDE,
BMS-528691,
N-Deshydroxyethyl dasatinib metabolite M4,
Dasatinib metabolite M4,
SCHEMBL1147163,
Target Protein-binding moiety 8,
CTK5G8813,
DTXSID60470341,
DOBZFFWLHXORTB-UHFFFAOYSA-N,
ZINC22056134,
AKOS030255256,
AC-30421,
HY-107447,
RT-014403,
CS-0028504,
FT-0666020,
A820302,
N-(2-chloranyl-6-methyl-phenyl)-2-[(2-methyl-6-piperazin-1-yl-pyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide,
N-(2-Chloro-6-methylphenyl)-2-(2-methyl-6-(piperazin-1-yl)pyrimidin-4-ylamino)thiazole-5-carboxamide,
CID11669430,
CID 11669430,
302962-49-8,